ACCEPT: A phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL)

被引：1
|
作者：
Johnson, Peter W. M. [1 ]
Caddy, Joshua [2 ]
Cumin, Tom [1 ]
Merton, Bridgen [1 ]
Maishman, Tom [2 ]
Galanopoulou, Angelic [2 ]
Griffiths, Gareth [2 ]
Davies, Andrew [1 ]
机构：
[1] CRUK Ctr, Southampton, Hants, England
[2] Southampton Clin Trials Unit, Southampton, Hants, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT162
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Rituximab, bevacizumab (avastin) and CHOP (RA-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL).
    Ganjoo, KN
    Gordon, L
    Robertson, MJ
    Horning, SJ
    BLOOD, 2004, 104 (11) : 389A - 389A
  • [42] Beta-2 Microglobulin As a Strong Prognostic Factor in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone
    Miyashita, Kazuho
    Tomita, Naoto
    Taguri, Masataka
    Suzuki, Taisei
    Ishiyama, Yasufumi
    Ishii, Yoshimi
    Numata, Ayumi
    Hattori, Yukako
    Yamamoto, Wataru
    Miyazaki, Takuya
    Tachibana, Takayoshi
    Takasaki, Hirotaka
    Matsumoto, Kenji
    Hashimoto, Chizuko
    Takemura, Sachiya
    Yamazaki, Etsuko
    Fujimaki, Katsumichi
    Sakai, Rika
    Motomura, Shigeki
    Ishigatsubo, Yoshiaki
    BLOOD, 2014, 124 (21)
  • [43] Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
    Micallef, Ivana N. M.
    Maurer, Matthew J.
    Wiseman, Gregory A.
    Nikcevich, Daniel A.
    Kurtin, Paul J.
    Cannon, Michael W.
    Perez, Domingo G.
    Soori, Gamini S.
    Link, Brian K.
    Habermann, Thomas M.
    Witzig, Thomas E.
    BLOOD, 2011, 118 (15) : 4053 - 4061
  • [44] Phase I Trial of Carfilzomib plus R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
    Hill, Brian T.
    Dean, Robert M.
    Jagadeesh, Deepa
    Garcia, Alex V. Mejia
    Pohlman, Brad
    Winter, Allison M.
    Krauspe, Ethan
    Collier, Patrick
    D'Andrea, Christopher
    Morrison, Ashley
    Lehmann, Sarah
    Tomlinson, Benjamin K.
    Cooper, Brenda
    de Lima, Marcos
    Ondrejka, Sarah L.
    Hsi, Eric D.
    Caimi, Paolo
    BLOOD, 2018, 132
  • [45] Phase III Trial of Subcutaneous Epcoritamab plus R-CHOP Versus R-CHOP Alone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE DLBCL-2
    Sehn, Laurie
    Chamuleau, Martine
    Lenz, Georg
    Clausen, Michael
    Haioun, Corinne
    Izutsu, Koji
    Davies, Andrew
    Zhu, Jun
    Oki, Toshiko
    Szafer-Glusman, Edith
    Conlon, Rebekah
    Chiou, Hueiyu
    Ipe, David
    Elliott, Brian
    Wu, Jun
    Salles, Gilles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S440 - S440
  • [46] R-IPI as a predictor of survival in patients with diffuse large cell B-cell lymphoma (DLBCL) treated with R-chop chemotherapy
    Siddiqui, M.
    Johnston, P. B.
    Micallef, I. N.
    Ansell, S. M.
    Colgan, J. P.
    Habermann, T. M.
    Inwards, D. J.
    Markovic, S. N.
    Ristow, K.
    Witzig, T. E.
    Porrata, L. F.
    ANNALS OF ONCOLOGY, 2008, 19 : 146 - 146
  • [47] Phase 3 trial of subcutaneous epcoritamab plus R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.
    Sehn, Laurie Helen
    Chamuleau, Martine
    Lenz, Georg
    Clausen, Michael
    Haioun, Corinne
    Izutsu, Koji
    Davies, Andrew John John
    Zhu, Jun
    Oki, Toshiko
    Szafer-Glusman, Edith
    Conlon, Rebekah
    Chiou, Hueiyu
    Ipe, David
    Elliott, Brian
    Wu, Jun
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma
    Micallef, Ivana N. M.
    Kahl, Brad S.
    Maurer, Matthew J.
    Dogan, Ahmet
    Ansell, Stephen M.
    Colgan, Joseph P.
    Geyer, Susan
    Inwards, David J.
    White, William L.
    Habermann, Thomas M.
    CANCER, 2006, 107 (12) : 2826 - 2832
  • [49] SERUM B2-MICROGLOBULIN LEVELS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): PROGNOSTIC SIGNIFICANCE UNDER TREATMENT WITH RITUXIMAB-CHOP (R-CHOP)
    Vassilakopoulos, T. P.
    Anastasopoulou, A.
    Constantinou, N.
    Angelopoulou, M. K.
    Stavroulaki, E.
    Kalpadakis, C.
    Sachanas, S.
    Pappis, V.
    Tsirkinidis, P.
    Moschoyiannis, M.
    Tsopra, O.
    Tzenou, T.
    Gassiamis, A.
    Yiakoumis, X.
    Kyrtsonis, M. C.
    Kokoris, S. I.
    Siakantaris, M. P.
    Dimou, M.
    Georgiou, G.
    Plata, E.
    Viniou, N. A.
    Variamis, E.
    Konstantopoulos, K.
    Panayiotidis, P.
    Papadaki, H.
    Pangalis, G. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 393 - 394
  • [50] Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma
    Kayamori, Kensuke
    Shono, Katsuhiro
    Onoda, Masahiro
    Yokota, Akira
    HEMATOLOGY, 2019, 24 (01) : 52 - 59
12345